Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT02253654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02253654
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02253654. Randomized; triple masking; primary purpose treatment. Start 2015-04-01 (actual); primary completion 2016-04-27 (actual). Results posted on 2017-05-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Condition
Renal Insufficiency, Chronic
Condition
Anemia
Condition
Renal Dialysis
Condition
Erythrocyte Transfusion
Intervention (Drug)
Epoetin alfa
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02253654
Content hash
bd952552491c12660edf9955477dcbb063aa251c07ecac694f8c511194f81467